

To compare the efficacy and safety of Ginkgo biloba extract EGb 761® and betahistine in the treatment of vertigo

Submission date 02/02/2012	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 19/03/2012	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 04/09/2014	Condition category Ear, Nose and Throat	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Vertigo is a type of dizziness, where there is a feeling of motion when one is stationary. The symptoms are due to a dysfunction of the vestibular system in the inner ear. It is commonly associated with vomiting or nausea, unsteadiness, and excessive sweating. Blurred vision, difficulty in speaking, a lowered level of consciousness, and hearing loss may also occur. Symptoms of vertigo can be acute and last then for just a few minutes or hours or it can be chronic, which is a continuous sensation. The beneficial effects of the Ginkgo biloba special extract EGb 761® on vestibular compensation have been demonstrated in preclinical and clinical studies. Patients show significantly better improvement with EGb 761® than with a placebo (dummy) drug. According to early studies, EGb 761® seems to be as effective as betahistine, one of the most popular drugs for treating vertigo. EGb 761® appears to be extremely well tolerated with few side effects and good compliance. The aim of this study is to compare the clinical effectiveness and safety of EGb 761® and betahistine in the treatment of vertigo.

Who can participate?

Male or female outpatients aged 45 or over with vertigo.

What does the study involve?

To determine their eligibility for the study, participants will undergo a physical examination, ECG and laboratory tests (blood sampling at the beginning and end of the study). Participants will then be randomly allocated to receive either EGb 761® or betahistine for 12 weeks. During the study visits participants will complete questionnaires to assess their symptoms.

What are the possible benefits and risks of participating?

According to abundant evidence from other studies and many years of use, there is no major risk linked to the intake of EGb 761® at this dose. The adverse events potentially associated with EGb 761®, such as gastrointestinal symptoms, headache and allergic skin reactions, are usually mild in nature. Bleeding has been observed in individual cases after long-term treatment with Ginkgo preparations, some of unknown origin and quality and in some instances while also being treated with anti-platelet or anti-coagulant drugs. However, specific studies with EGb 761® at

dose levels up to 480 mg per day have shown no effect on coagulation or platelet function. Betahistine may have the following side effects: immune system disorders: hypersensitivity (allergic) reactions (such as anaphylaxis) have been reported; gastrointestinal disorders: in some cases mild gastric complaints have been observed, these can normally be dealt with by taking the dose during meals; skin and subcutaneous tissue disorders: in very rare cases cutaneous hypersensitivity reactions have been reported, in particular angioneurotic oedema (sudden onset of face, neck or limb swelling), urticaria (hives), rash and pruritus (itchiness). There is hardly any risk associated with the tests and examinations required by this study, except for a small risk of infection during blood sample drawing. On the other hand, based on the earlier clinical findings described above it can be expected that patients will benefit from the treatment with EGb 761® or betahistine.

Where is the study run from?

The study is running from ten sites/university-based clinics in Ukraine.

When is the study starting and how long is it expected to run for?

The study ran from September 2011 to September 2012.

Who is funding the study?

Dr Willmar Schwabe GmbH & Co. KG (Germany).

Who is the main contact?

Mrs Anna Wacker

anna.wacker@schwabe.de

Contact information

Type(s)

Scientific

Contact name

Prof L. I. Sokolova

Contact details

Bogomolets National Medical University

Chair of Nervous Diseases

Kyiv Clinical Hospital 4

Neurological department 2

17, Solomianska St.

Kiev

Ukraine

03110

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

523001.01.100

Study information

Scientific Title

Randomized, reference-controlled, double-blind phase III trial to compare the efficacy and safety of Ginkgo biloba extract EGb 761® and betahistine in the treatment of vertigo

Study objectives

The objective of this clinical trial is to compare the clinical efficacy and safety of the Ginkgo biloba special extract EGb 761® and betahistine in the treatment of vertigo.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Central Ethics Committee, Ministry of Health Ukraine, 16/02/2011

Study design

Randomized reference-controlled parallel-group double-blind trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Vertigo

Interventions

2x120 mg Ginkgo biloba extract EGb 761® or 2x16 mg betahistine per day for 12 weeks

Intervention Type

Drug

Phase

Phase III

Drug/device/biological/vaccine name(s)

Ginkgo biloba extract EGb 761®, betahistine

Primary outcome measure

1. 11-point Numeric Analogue Scale (NAS), measurement of subjectively perceived severity of vertigo
 2. Short form of the Vertigo Symptom Scale (VSS-SF), subjectively perceived severity of vertigo symptoms
 3. Sheehan Disability Scale (SDS), assessment of the impairment of daily living
 4. Clinical Global Impression (CGI), physician rated, for changes from baseline as well as as for the assessment of the tolerability
- Measured at screening, baseline (Day 0), Week 4, Week 8 and the final visit Week 12

Secondary outcome measures

1. Physical examination
 2. Neuro-otological examination
 3. Electrocardiogram (ECG)
 4. Vital signs
 5. Adverse events
 5. Laboratory tests
- Measured at baseline and end of trial

Overall study start date

30/09/2011

Completion date

30/09/2012

Eligibility**Key inclusion criteria**

1. Diagnosis of vertiginous syndrome not otherwise specified (ICD-10, H 81.9) or peripheral vertigo not otherwise specified (ICD-10, H81.3). (This excludes specific disorders of vestibular function such as Ménière's disease, benign paroxysmal vertigo, vestibular neuronitis, Lermoyez syndrome and central positional nystagmus as well as acute dysfunction of the inner ear)
2. Symptoms of vertigo for at least 3 months
3. At least moderate severity of vertigo, i.e. a score of ≥ 3 on the Numeric Analogue Scale (NAS) at screening
4. Male or female outpatients aged ≥ 45 years
5. Signed Informed consent in accordance with the legal requirements
6. Sufficient language skills, readiness and ability on the part of the patient to comply with the physicians instructions, respond to all interview questions, and to fill in the self-assessment scales without evident difficulties and without the assistance of an interpreter
7. Negative pregnancy test at screening visit in females of childbearing potential (non-childbearing potential is defined as post-menopause for at least one year or surgical sterilization or hysterectomy at least three months before study start)
8. Use of adequate contraception by female with childbearing potential (hormonal: oral, implants, hormonal intrauterine contraceptive device (IUCD); or intrauterine contraception devices)

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

160 patients

Key exclusion criteria

1. Participation in another experimental drug trial at the same time or within the past 12 weeks before enrolment
2. Treatment in the last 12 weeks with Ginkgo-biloba preparations or in the last 8 weeks with any cerebral blood circulation enhancing medications or antiemetics, anti-vertigo agents or antidementia drugs
3. More than 2 years present therapy-resistant vertigo
4. Morbus Ménière or Lermoyez syndrome
5. Current hospitalization of the patient
6. Contraindication for the treatment with betahistine: pheochromocytoma or bronchial asthma
7. History or evidence of alcohol and/or substance abuse or dependence within the last 5 years
8. Unacceptability to discontinue or likelihood to need medication during the study that is prohibited as concomitant treatment. The following medication is not allowed during the study:
 - 8.1. Any psychotropic drugs including CNS stimulants, tranquilizers / hypnotics (e.g. benzodiazepines, non-benzodiazepine tranquilizers/anyolytics like zopiclone or zolpidem, barbiturates), neuroleptics / antipsychotics, antidepressants, antiepileptics, antihistaminics and nootropics
 - 8.2. Treatments for neuro-degenerative diseases (e. g. tacrine, donepezil, rivastigmin, metrifonate, galanthamin or any other cholinesterase inhibitor or cholinergic agonist, N-Methyl-D-Aspartate (NMDA)-antagonists (e.g. memantine), nimodipine, vasodilators and haemorheological agents with cerebral activity (e. g. bencyclane, buflomedil, hydergine), other cognition enhancers (e. g. piracetam)
 - 8.3. Anticholinergic and anti-Parkinson drugs (e.g. oxybutynin, tolterodine, trospium chloride, propiverin, l-dopa, selegilin, amantadine, biperiden, benzatropin, metixen etc)
 - 8.4. Anticonvulsants (carbamazepin, phenytoin)
 - 8.5. Antiemetics, anti-vertigo agents
 - 8.6. Aminoglycoside antibiotics
 - 8.7. Long-term therapy with salicylates (> 100mg per day)
 - 8.8. Loop diuretics: furosemide, bumetanide
 - 8.9. Antineoplastics (cisplatin, carboplatin)
 - 8.10. Quinine
9. Clinically significant abnormality of ECG and/or laboratory value(s)
10. Severe, uncontrolled cardiovascular disease, especially:
 - 10.1. Severe (stage IV acc. to the Canadian Cardiovascular Society) or unstable angina pectoris
 - 10.2. Decompensated congestive heart failure [New York Heart Association (NYHA) stage IV]
 - 10.3. Myocardial infarction within the last 6 months
 - 10.4. Uncontrolled hypertension (systolic pressure >180 mmHg, diastolic pressure >115 mmHg)
 - 10.5. Known clinically significant cardiac arrhythmias
 - 10.6. Atrial fibrillation with known or suspected left ventricular myocardial dysfunction.
11. Any severe

- 11.1. Hepatic, renal disorders [serum creatinine or serum aspartate amino transferase (ASAT), alanine amino transferase (ALAT) or Gamma-glytamy] transpeptidase (Gamma GT)] above 3 times the upper limit of the reference range
- 11.2. Insulin dependent diabetes mellitus
- 11.3. Respiratory diseases
- 11.4. Metabolic disorder or progressive diseases, such as cancer (exception: prostate cancer T1N0M0 which does not require treatment within the next 7 months except hormone therapy)
- 11.5. Haematologic diseases
- 11.6. Neurological diseases (epilepsy or a history of seizure disorder or treatment with anticonvulsants for epilepsy or seizures, Parkinsons disease, multiple sclerosis, injury with residual neurologic deficits)
- 12. Severe head trauma, brain tumor, apoplexy
- 13. Neuritis vestibularis, herpes zoster oticus
- 14. Vertigo due to specific somatic diseases, e.g. orthostatic hypotension, hypertension, hematological or metabolic disorders
- 15. Benign paroxysmal positional vertigo
- 16. Known hypersensitivity to Ginkgo biloba extract or betahistine dihydrochloride or to any components of the preparations
- 17. Gastrointestinal disorders with uncertain absorption of orally administered drugs (e.g. partial or total gastrectomy, enterectomy, inflammatory bowel disease, celiac disease, symptomatic lactose intolerance, other disorders associated with chronic diarrhoea)
- 18. Pregnancy, lactation

Date of first enrolment

30/09/2011

Date of final enrolment

30/09/2012

Locations

Countries of recruitment

Ukraine

Study participating centre

Bogomolets National Medical University

Kiev

Ukraine

03110

Sponsor information

Organisation

Dr. Willmar Schwabe GmbH & Co. KG (Germany)

Sponsor details

Willmar-Schwabe-Str. 4
Karlsruhe
Germany
76227

Sponsor type
Industry

ROR
<https://ror.org/043rrkc78>

Funder(s)

Funder type
Industry

Funder Name
Dr Willmar Schwabe GmbH & Co. KG (Germany)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/03/2014		Yes	No